et al.

Early Clinical Development Planning via Biomarkers, Clinical Endpoints, and Simulation: A Case Study to Optimize for Phase 3 Dose Selection

Research Designs for Proof-of-Concept Chronic Pain Clinical Trials: IMMPACT Recommendations

Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes

An Intra-Articular, Extended-Release Formulation of Triamcinolone Acetonide Prolongs and Amplifies Analgesic Effect in Patients With Osteoarthritis of the Knee: a Randomized Clinical Trial

Impact of Phase 2b Strategies on Optimization of Drug Development Programs

A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma

Heart Failure and Mortality Outcomes in Patients With Type 2 Diabetes Taking Alogliptin vs. Placebo in EXAMINE: a Multicentre, Randomised, Double-blind Trial

Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukaemia (VALOR): A Randomised, Controlled, Double-blind, Multinational, Phase 3 Study

DIA’s Adaptive Design Scientific Working Group (ADSWG) Best Practices Case Studies for “Less Well-understood” Adaptive Designs

Addressing Challenges and Opportunities of “Less Well-Understood” Adaptive Designs